featured
Neurotoxicity of Nab-Paclitaxel vs Solvent-Based Paclitaxel in HER2-Negative Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Oncologist
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients With Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer
Oncologist 2019 Apr 25;[EPub Ahead of Print], E Ciruelos, M Apellániz-Ruiz, B Cantos, N Martinez-Jáñez, C Bueno-Muiño, MJ Echarri, S Enrech, JA Guerra, L Manso, T Pascual, C Dominguez, JF Gonzalo, JL Sanz, C Rodriguez-Antona, JM SepúlvedaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.